Name: FDA Catalyst: Example Drug
Start: 2026

Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

XTXORTX Therapeutics Inc.

$2.05

+0.03 (+1.49%)

Market Cap

3.04 M

EPS

-2.63

P/E Ratio

Value Trade

28.57 K

4.31 %

Week

-13.15 %

1 Month

11.51 %

3 Month

-17.42 %

6 Month

-98.57 %

5 Year

-98.57 %

All Time

Cash Data

Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo

Overview

Volume

2.82 K

52 Week Range

1.73 - 7.05

% held by Insiders

8.22 %

% held by Institutions

0.18 %

Enterprise Value

2.80 M

Total Shares

1.73 M

Short %

1.48 %

Float Shares

1.59 M

Company Description

Employees:3

https://www.xortx.com

locked

Upcoming Catalyst

Catalyst	Drug/Treatment	Stage	Probability of Approval	Description	Drug Type	Therapeutic Area
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology
PDUFA 2026	Example Drug Treatment for example condition requiring FDA review	Phase 3	-%	FDA review of the new drug application for the treatment of example condition. Read More	Small Molecule	Oncology

Unlock Upcoming Catalyst data

Catalyst Timeline

Dated clinical, regulatory & corporate events for XORTX Therapeutics Inc.

313Total events

6Upcoming

46Tier-1 (high impact)

2018 – 2027Coverage

Upcoming catalysts 2

TBD

T1NDA Submission

Subscribe to view catalyst details

XORLOFiled

TBD

T1NDA Submission

Subscribe to view catalyst details

XRx-026Filed

Event history 2

TBD

◆Type B MeetingXRx-026FiledFDA Meeting

Subscribe to view catalyst details

TBD

◆Management ChangeCorporate

Subscribe to view catalyst details

Unlock the full Catalyst Timeline

Past FDA Catalysts & PDUFA Decisions

Date	Drug	Catalyst	Stage	Outcome	Reaction	Event Move %	Best Trade %
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%
—	Example Drug	Phase 3 data readout	Phase 3	—	–	0%	0%

Unlock Historical Catalyst data

Drug Pipeline Intelligence

Unlock Drug Pipeline Intelligence

Clinical Trial Results

Drug Name	Indications	Phase	Date	Trial Results Summary	Title
XORLOTM Orphan	autosomal dominant polycystic kidney disease (ADPKD)	Phase 3	2023-01-19	substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform; increased dose proportionality compared to non-formulated oxypurinol; average increase of exposure of ~40% in oxypurinol compared to the fasted state; increased bioavailability of 100% or more could be achieved with test formulations compared to non-formulated oxypurinol alone Read More	XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial Read More
XORLOTM Orphan	autosomal dominant polycystic kidney disease (ADPKD)	Phase 3	2023-01-19	substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform; increased dose proportionality compared to non-formulated oxypurinol; average increase of exposure of ~40% in oxypurinol compared to the fasted state; increased bioavailability of 100% or more could be achieved with test formulations compared to non-formulated oxypurinol alone Read More	XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial Read More
XORLOTM Orphan	autosomal dominant polycystic kidney disease (ADPKD)	Phase 3	2023-01-19	substantial increase in the bioavailability of oxypurinol with the XORLOTM formulation platform; increased dose proportionality compared to non-formulated oxypurinol; average increase of exposure of ~40% in oxypurinol compared to the fasted state; increased bioavailability of 100% or more could be achieved with test formulations compared to non-formulated oxypurinol alone Read More	XORTX Announces Positive Topline Results from XRX-OXY-101 Clinical Trial Read More

Unlock Clinical Trial Results data

Inside Trades

YEARLY INSIDER TRANSACTIONS

Sector Avg.

INSIDERS
SOLDINSIDERS
BOUGHT

POSITIVE SENTIMENT Based on 22 Insiders Transactions

Unlock Inside Trades data

Show Data

Hedge Funds

Shares Held

2040.00B1530.00B1020.00B510.00B0

Q3
2024

Q4
2024

Q1
2025

Q2
2025

HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT

POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter

18 buying (3 new)·9 selling (1 exited)·2 unchanged

Fund Count

60%

Share Volume

25%

Conviction

15%

Hedge Funds invested in XRTX

HedgeFund Name ( 3 )	% of Portfolio	Current MV -	Shares Owned -
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K
Example Capital Management	2.5 %	15.00 M	250.00 K

Unlock Hedge Funds table data

XRTX Institutional Ownership Trends

Current Insider %

5.20%

—+0.00%

Current Institutional %

62.40%

—+0.00%

Total Ownership

67.60%

Insider + Institutional

Data Points

1 Ticker(s)

Option Chain Statistics

Expiration	Volume			Open Interest			Implied Volatility Calls			Implied Volatility Puts
Expiration	Calls	Puts	Put-Call Ratio	Calls	Puts	Put-Call Ratio	IV	OiWaIv	VWaIv	IV	OiWaIv	VWaIv

Unlock Option Chain Statistics data

Option Chain

Calls			Strike	Puts
Last Price	Volume	Open Interest	Strike	Last Price	Volume	Open Interest
No data available

Unlock Option Chain data

Unlock Options Chart data

Open interest

Today's Open Interest

1.00 M

Put-Call Ratio

1.1

Put Open Interest

480.00 K

Call Open Interest

520.00 K

Open Interest Avg (30-day)

900,000

Today vs Open Interest Avg (30-day)

11.11%

Option Volume

Today's Volume

750.00 K

Put-Call Ratio

0.95

Put Volume

360.00 K

Call Volume

390.00 K

Volume Avg (30-day)

800,000

Today vs Volume Avg (30-day)

-6.25%

Company News

XORTX Appoints New Director

XORTX Therapeutics has appointed Depesh Narotam as an independent director effective July 27, 2026. Narotam brings over 20 years of experience in financial services, particularly in debt financing and strategic partnerships. His appointment is expected to enhance the board's governance and support the advancement of the company's clinical programs targeting gout and kidney diseases.

-XRTX

Jun 15, 2026

XRTXGeneral

XORTX Therapeutics Inc. has received a compliance letter from Nasdaq after meeting the minimum bid price requirement of $1.00 per share. This was achieved following a 1 for 5 reverse stock split implemented on April 6, 2026. The company is focused on developing therapies for gout and progressive kidney disease, with several products in various stages of development.

-XRTX

Apr 14, 2026

XRTXGeneral

XORTX Therapeutics Inc. announced the results of its annual and special meeting held on March 24, 2026. Approximately 35% of shares were represented, leading to the approval of all proposed matters, including the election of five management nominees and the appointment of auditors. The company continues to focus on developing therapies for gout and kidney diseases.

-XRTX

Mar 25, 2026

XRTXGeneral

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Therapeutics has announced the acquisition of the VB4-P5 Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems. This program includes a novel small molecule aimed at treating kidney disease, currently at the pre-IND stage. The acquisition is valued at USD $3 million, payable in XORTX shares, and is expected to close within 90 days, pending regulatory approvals.

-XRTX

Sep 4, 2025

XRTXConferences/Events

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

XORTX Therapeutics Inc. is inviting investors to a webinar on September 10, 2025, featuring CEO Dr. Allen Davidoff. The session will cover the company's innovative therapies for gout and kidney diseases, including the lead program XRx-026, which is set for a New Drug Application filing in 2026. A live Q&A will follow the presentation.

-XRTX

Sep 3, 2025

XRTXFDA Updates

XORTX Therapeutics Inc. has announced its participation in the Microcap Conference from January 28 to 30, 2025, in Atlantic City, NJ, to engage with investors and update them on their newly announced gout program. CEO Dr. Allen Davidoff expressed excitement about the opportunity to discuss plans for advancing the XRx-026 program for gout and the XRx-008 program for autosomal dominant polycystic kidney disease. The presentation will include details on a New Drug Application filing and will be available on the company's website afterward.

-XRTX

Jan 22, 2025

XRTXGeneral

NOTICE OF CHANGE OF AUDITOR

XORTX Therapeutics Inc. has announced a change of auditor, appointing Davidson & Company LLP as its new auditor effective January 16, 2025, following the resignation of Smythe LLP. The decision was approved by both the Audit Committee and the Board of Directors. Importantly, no reportable events or disagreements occurred between the prior and new auditor. The former auditor did not issue any modified opinions on the company's financial statements prior to their resignation.

-XRTX

Jan 17, 2025

XRTXGeneral

▼ -5.8%on this newsshared move

XORTX Announces Change of Auditor

XORTX Therapeutics Inc. has announced a change of auditor from Smythe LLP to Davidson & Company LLP, effective January 16, 2025. The board accepted the resignation of the former auditor, and there were no reservations in their audit reports. This change is expected to enhance oversight as the company continues its focus on developing therapies for progressive kidney disease and gout.

XORTX Adds Late Stage Gout Program to Pipeline

XORTX Therapeutics Inc. has launched a late-stage program for a new drug, XRx-026, aimed at treating gout in patients who cannot tolerate allopurinol. The company is preparing for a New Drug Application with the FDA and is seeking orphan drug designation for the new therapy. With a substantial number of patients suffering from gout and intolerance to current treatments, XORTX plans to address this unmet medical need in the market. Additionally, the company continues to advance its other clinical programs in kidney disease treatments.

-XRTX

Dec 19, 2024

XRTXGeneral

XORTX Strengthens Executive Team

XORTX Therapeutics Inc. announced the appointment of Dr. Michael Bumby as its new Chief Financial Officer, replacing James Fairbairn. Dr. Bumby brings over 20 years of experience in the biotech industry, having held prominent roles at Eli Lilly and other pharmaceutical companies. The leadership of XORTX is optimistic about Dr. Bumby’s qualifications, believing his background will significantly contribute to the company’s development goals. The company has also granted stock options to Dr. Bumby as part of his compensation package.

-XRTX

Dec 12, 2024

XRTXConferences/Events

XORTX Announces Presentation at the Rare and Genetic Disease Summit

XORTX Therapeutics Inc. has announced that Dr. Allen Davidoff will present at the Rare and Genetic Kidney Disease Summit in Boston, focusing on Autosomal Dominant Polycystic Kidney Disease (ADPKD). The presentation will discuss recent research indicating genetic factors linked to the over-expression of xanthine oxidase and their implications for disease progression. XORTX plans to utilize these findings to develop personalized therapies for individuals at risk of ADPKD and to conduct a clinical trial to further explore these genetic factors in patients.

-XRTX

Oct 24, 2024

XRTXConferences/Events

▼ -5.1%on this news

XORTX Therapeutics Inc. has officially launched a new precision medicine program focused on progressive kidney disease. This initiative is based on independent peer-reviewed research that connects genetic factors to the over-expression of xanthine oxidase, which has implications for several diseases. The program aims to create diagnostics that identify genetic factors and tailor treatments for subpopulations impacted by these conditions, particularly in patients with autosomal dominant polycystic kidney disease. Overall, this initiative positions XORTX to leverage recent scientific discoveries for innovative therapeutic strategies.

-XRTX

Sep 13, 2024

XRTXGeneral

XORTX Therapeutics Inc. has announced its upcoming annual and special meeting of shareholders scheduled for September 12, 2024, at its Calgary location. Shareholders of record as of August 1, 2024, are entitled to attend and vote at the meeting. The notice outlines the process for proxy voting and the necessary steps for transfer of shares. Further details will be provided in the management information circular.

-XRTX

Aug 20, 2024

XRTXConferences/Events

XORTX Announces Presentation at American Society of Nephrology – Kidney Week 2024

XORTX Therapeutics announced that an abstract titled 'Xanthine oxidase in rats, mice and humans with polycystic kidney disease' has been accepted for presentation at the American Society of Nephrology's Kidney Week 2024. The study, conducted at the University of Colorado, aims to explore the relationship between xanthine oxidase activity and kidney disease progression. The results will contribute to a better understanding of cyst growth and kidney function decline in patients with polycystic kidney disease. Further updates on the study will be provided in November.

-XRTX

Jun 4, 2024

XRTXConferences/Events

XORTX to Present at BIO International Convention 2024

XORTX Therapeutics Inc. announced its participation in the BIO International Convention 2024, where CEO Dr. Allen Davidoff will present the company's progress and future plans. This is the second time XORTX is invited to this convention, reflecting its growing reputation in the biotechnology sector. The event will take place from June 3rd to 6th in San Diego, California, with Dr. Davidoff's presentation scheduled for June 4th. XORTX aims to advance its innovative therapies for kidney disease through these partnerships and discussions.

XORTX Reprices Balance of Warrants Issued in Connection with October 2021 US IPO

XORTX Therapeutics Inc. has received TSX Venture Exchange approval to amend the terms of outstanding common share purchase warrants issued during its October 2021 IPO. The changes include a new exercise price of USD $5.00, significantly down from the original price of USD $42.93, and an acceleration provision if the company’s stock price exceeds USD $6.50 for ten consecutive trading days. While this could make the warrants more appealing, investors will need to see the share price increase significantly for the provisions to take effect.

-XRTX

Apr 30, 2024

XRTXGeneral

XORTX Therapeutics has announced the addition of Dr. Ronald Perrone to its Clinical Advisory Board. Dr. Perrone is a prominent nephrologist with significant experience in treating autosomal dominant polycystic kidney disease (ADPKD). His involvement is expected to enhance XORTX's clinical programs, particularly the registration trial for XRX-OXY-201, aimed at slowing ADPKD progression. This appointment reflects XORTX's commitment to advancing innovative therapies in kidney disease treatment.

-XRTX

Mar 19, 2024

XRTXPhases

XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial

XORTX Therapeutics has highlighted its significant achievements in 2023 and outlined its objectives for 2024. Key milestones include receiving Orphan Drug Designation from the FDA for its XRx-008 program targeting Autosomal Dominant Polycystic Kidney Disease, and progress towards conducting a registration clinical trial. The company also aims for accelerated approval of its proprietary formulation, XORLO™, and has undertaken an independent commercial assessment suggesting substantial future sales potential. XORTX continues to enhance its strategic plan and team, gearing up for further clinical development.

-XRTX

Mar 4, 2024

XRTXGeneral

▲ +5.1%on this news· ran to +47% by day 1

XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units

XORTX Therapeutics Inc. has announced the successful closing of a second tranche under its previously announced offering, raising CAD $224,850. This contributes to total gross proceeds of CAD $2.7 million from the offering, aimed at general corporate and working capital purposes. The offering included common share units and associated warrants with a stipulated exercise price. The company is focused on developing therapies for progressive kidney disease, highlighting the financial backing intended to support its clinical initiatives.

-XRTX

Feb 15, 2024

XRTXGeneral

XORTX Therapeutics Inc. has announced an At The Market Offering Agreement with H.C. Wainwright & Co., allowing the company to sell its common shares with an aggregate offering price of up to $3.7 million. The proceeds will primarily be used for working capital and other corporate purposes. This move signals XORTX's ongoing commitment to financing its pipeline aimed at innovative treatments for progressive kidney disease.

-XRTX

Nov 10, 2023

XRTXGeneral

XORTX Therapeutics Inc. has called a special meeting of shareholders on October 25, 2023, to discuss a consolidation of issued shares for compliance with NASDAQ listing requirements. CEO Dr. Allen Davidoff emphasized the company's commitment to maintaining its NASDAQ presence despite market challenges. The meeting materials have already been distributed to shareholders. XORTX is advancing its late-stage clinical programs aimed at treating kidney-related conditions.

-XRTX

Sep 28, 2023

XRTXConferences/Events

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2023

XORTX Therapeutics Inc. announced that an abstract on its research regarding the effects of lowering uric acid in a mouse model of polycystic kidney disease has been accepted for presentation at the American Society of Nephrology's Kidney Week 2023. The study, conducted at the University of Colorado, indicates that uric acid levels, even when not saturating, can accelerate kidney damage. XORTX plans to share more details during the presentation scheduled for November 2, 2023. This research could offer new insights into therapeutic strategies for patients with autosomal dominant polycystic kidney disease (ADPKD).

-XRTX

Sep 11, 2023

XRTXConferences/Events

XORTX Announces Participation at Upcoming Investor Conferences

XORTX Therapeutics Inc. announced its participation in several upcoming investor conferences, allowing the company to present its clinical advancements in treating progressive kidney disease. The CEO, Dr. Allen Davidoff, will represent the company at the H.C. Wainwright Global Investment Conference and other significant events in September and October 2023. XORTX focuses on developing therapies for conditions such as Autosomal Dominant Polycystic Kidney Disease (ADPKD) and Type 2 Diabetic Nephropathy.

XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Therapeutics Inc. has received a 180-day extension from Nasdaq to comply with the minimum bid price requirement of $1.00 per share, following an initial notification of non-compliance. The new deadline is set for November 20, 2023, during which the company must maintain the necessary share price for at least 10 consecutive business days. Should XORTX fail to meet this requirement, it faces the risk of being delisted, though the company may appeal any delisting determination. The company is exploring options to regain compliance and maintain its Nasdaq listing.

-XRTX

Apr 21, 2023

XRTXFDA Updates

XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

XORTX Therapeutics Inc. has announced that its compound oxypurinol has received Orphan Drug Designation from the FDA for the treatment of autosomal dominant polycystic kidney disease (ADPKD). This designation, while not an approval, is viewed as a crucial step in the company's efforts to seek market authorization. The designation benefits include potential exclusivity in marketing, tax credits for clinical testing, and regulatory support. A meeting with the FDA is scheduled for May 1, 2023, to discuss the upcoming Phase 3 clinical program for XORLOTM.

-XRTX

Mar 14, 2023

XRTXFDA Updates

XORTX Therapeutics has announced positive topline results from its XRX-OXY-101 clinical trial, which evaluated the pharmacokinetics of its proprietary formulation XORLOTM. The study involved 88 subjects and demonstrated no safety issues, with significant improvements in the bioavailability of oxypurinol. The results from the trial will aid in developing dosing recommendations for the upcoming Phase 3 registration trial targeting individuals with autosomal dominant polycystic kidney disease (ADPKD). These advancements are expected to enhance the company’s ability to address the progression of kidney disease.

-XRTX

Jan 3, 2023

XRTXGeneral

XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

XORTX Therapeutics has submitted a Patent Cooperation Treaty application for a new patent focusing on diagnosing and treating individuals at risk of progressive polycystic kidney disease (PKD). This patent is based on research findings that indicate a novel method for identifying patients with aberrant purine metabolism, which is linked to accelerated kidney disease progression. The company aims to develop personalized medicinal approaches to manage and mitigate health issues associated with PKD. This innovative work is particularly aimed at improving outcomes for those most impacted by this condition.

XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study

CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

-XRTX

Dec 8, 2022

XRTXGeneral

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

CALGARY, Alberta, Dec. 08, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

-XRTX

Nov 28, 2022

XRTXPhases

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

CALGARY, Alberta, Nov. 28, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

-XRTX

Nov 3, 2022

XRTXConferences/Events

XORTX Presents New Proof of Concept Data at American Society of Nephrology

● Xanthine Oxidase Inhibition with XRx-008 Blocks Uric Acid Induced Increase in Total Kidney Weight in Polycystic Kidney Disease ● CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU)

-XRTX

Oct 26, 2022

XRTXGeneral

CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease

-XRTX

Sep 1, 2022

XRTXConferences/Events

XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022

CALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is ple

XORTX Announces Positive Topline Results from Part 2 Pharmacokinetics Bridging Study

CALGARY, Alberta, Aug. 22, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

-XRTX

Jun 21, 2022

XRTXConferences/Events

XORTX Announces “Fireside Chat” with XORTX CEO

CALGARY, Alberta, June 21, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is ple

-XRTX

Jun 13, 2022

XRTXConferences/Events

▼ -12.3%on this news

XORTX Therapeutics Announces Filing of Provision Patent for Polycystic Kidney Disease

CALGARY, Alberta, Dec. 21, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to

-XRTX

Dec 10, 2021

XRTXGeneral

▼ -6.4%on this news· ran to -19% by day 3

XORTX Therapeutics Announces Publication of Mt. Sinai Study of Hospitalized COVID-19 Patients

CALGARY, Alberta, Dec. 10, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to

-XRTX

Dec 9, 2021

XRTXGeneral

XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners

CALGARY, Alberta, Dec. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced tod

CALGARY, Alberta, Nov. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced that it has is

-XRTX

Nov 4, 2021

XRTXGeneral

XORTX Therapeutics Clarifies Halt of Trading in Canada and Timing for Commencement of Trading on TSX Venture Exchange

CALGARY, Alberta, Nov. 04, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (TSXV: XRTX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, wishes to clarify that the Com

-XRTX

Nov 2, 2021

XRTXFDA Updates

XORTX Therapeutics Receives Final Approval to List on the TSX Venture Exchange

CALGARY, Alberta, Nov. 02, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce that it h

-XRTX

Oct 15, 2021

XRTXGeneral

▼ -6.2%on this news· ran to -19% by day 3

XORTX Therapeutics Announces Closing of US$12 Million Public Offering

CALGARY, Alberta, Oct. 15, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, today announced the closing of a

-XRTX

Oct 14, 2021

XRTXPhases

XORTX Announces Results from Mount Sinai’s COVID-19 Clinical Study

CALGARY, Alberta, Oct. 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX | NASDAQ: XRTX), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce and share

-XRTX

Oct 14, 2021

XRTXConferences/Events

CALGARY, Alberta, Feb. 22, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Dave Matthews as

-XRTX

Jan 29, 2018

XRTXGeneral

XORTX Therapeutics Announces Appointment of Allan Williams and Paul Van Damme

CALGARY, Alberta, Jan. 29, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX), a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the appointment of Allan Williams and Paul Van D

Competitive Position

How XRTX ranks across every disease it competes in

Competitive Position is a premium feature

See how XRTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.

Start free trial

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

M&A Tracker

News

Blogs

Modality Leaderboard

API

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

$2.05

Cash Data

Overview

Company Description

Upcoming Catalyst

Catalyst Timeline

Upcoming catalysts 2

Event history 2

Past FDA Catalysts & PDUFA Decisions

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Hedge Funds

Hedge Funds invested in XRTX

XRTX Institutional Ownership Trends

Option Chain Statistics

Option Chain

Open interest

Option Volume

Company News

XORTX Appoints New Director

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Announces Closing of US$5 Million Public Offering

XORTX Announces US$5 Million Public Offering

XORTX Meets Nasdaq Continued Listing Requirements

XORTX Announces Closing of Acquisition of Vectus Kidney Anti-fibrotic Asset

XORTX Confirms Effective Date of Share Consolidation

XORTX Announces Change of Effective Date of Share Consolidation

XORTX Announces Results of Annual and Special Meeting of Shareholders

XORTX Announces Share Consolidation

XORTX Reports that Shareholders Approved the Share Consolidation at the Annual General Meeting

XORTX Announces Substitute Director Nominees for its Upcoming Annual and Special Meeting of Shareholders

XORTX Reports that Independent Proxy Advisory Firms Recommend XORTX Shareholders Vote “For” the Share Consolidation

XORTX Announces Filing and Mailing of the Meeting Documents in Connection with the Annual and Special Meeting of Shareholders

3710 - 33rd Street NW, Calgary, Alberta, Canada T2L

XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

XORTX Announces Pioneering Research on Genome-Wide Pathogenic Pathways in Gout and Provides a Corporate Update

XORTX Announces Closing of US$1.1 Million Registered Direct Offering

Source: XORTX Therapeutics Inc.

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10

XORTX Initiates IND Preparation for XORLO™ in Gout Program

XORTX Completes USD $114,500 Private Placement

XORTX Provides Corporate Update and Planned Activities for 2025 / 2026

XORTX Announces USD $114,500 Private Placement

XORTX Completes Non-Brokered Private Placement of Units

XORTX Announces USD $925,000 Private Placement

XORTX Announces USD $3 Million Offering

XORTX Provides Update on FDA Type B Meeting Request

XORTX Announces Grant of European Patent

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

XORTX Announces Update for Discussion with the FDA